These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2372673)

  • 41. Microvascular invasion in prostate cancer: prognostic significance in patients treated by radical prostatectomy for clinically localized carcinoma.
    van den Ouden D; Kranse R; Hop WC; van der Kwast TH; Schröder FH
    Urol Int; 1998; 60(1):17-24. PubMed ID: 9519416
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy.
    Zagars GK; Ayala AG; von Eschenbach AC; Pollack A
    Int J Radiat Oncol Biol Phys; 1995 Jan; 31(2):237-45. PubMed ID: 7836075
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Histological effects of endocrine therapy on prostatic cancer].
    Isaka S; Akakura K; Shimazaki J; Kumamoto Y; Kubo T; Yamanaka H; Akaza H; Aso Y; Okada K; Baba S
    Nihon Hinyokika Gakkai Zasshi; 1990 Oct; 81(10):1530-6. PubMed ID: 2273705
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved local control and survival for surgically staged patients with locally advanced prostate cancer treated with up-front low dose rate iridium-192 prostate implantation and external beam irradiation.
    Stromberg J; Martinez A; Benson R; Garton G; Diokno A; Gonzalez J; Zincke H; Schray M; Edmundson G; Brabbins D
    Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):67-75. PubMed ID: 8270460
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Longitudinal evaluation of cytogenetic aberrations in prostatic cancer: tumours that recur in time display an intermediate genetic status between non-persistent and metastatic tumours.
    Alers JC; Krijtenburg PJ; Hop WC; Bolle WA; Schröder FH; van der Kwast TH; Bosman FT; van Dekken H
    J Pathol; 1998 Jul; 185(3):273-83. PubMed ID: 9771481
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incidental carcinoma of the prostate: an analysis of the predictors of progression.
    Lowe BA; Listrom MB
    J Urol; 1988 Dec; 140(6):1340-4. PubMed ID: 3193495
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden.
    Johansson JE; Holmberg L; Johansson S; Bergström R; Adami HO
    JAMA; 1997 Feb; 277(6):467-71. PubMed ID: 9020270
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incidental carcinoma of the prostate: selection for deferred treatment.
    Beynon LL; Busuttil A; Newsam JE; Chisholm GD
    Br J Urol; 1983 Dec; 55(6):733-6. PubMed ID: 6652446
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nodal involvement as a prognostic indicator in patients with prostatic carcinoma.
    Prout GR; Heaney JA; Griffin PP; Daly JJ; Shipley WU
    J Urol; 1980 Aug; 124(2):226-31. PubMed ID: 7401236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Extended follow-up of stage A1 carcinoma of prostate.
    Thompson IM; Zeidman EJ
    Urology; 1989 Jun; 33(6):455-8. PubMed ID: 2728146
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship of DNA content to conventional prognostic factors in clinically localised carcinoma of the prostate.
    Ritchie AW; Dorey F; Layfield LJ; Hannah J; Lovrekovich H; deKernion JB
    Br J Urol; 1988 Sep; 62(3):245-60. PubMed ID: 3191338
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Histological determinants of the vascular surface in prostatic carcinoma.
    Barth PJ; Ghafouri-Sanati H; Köhler HH; Bittinger A; Riedmiller H
    Urol Res; 1997; 25(5):303-8. PubMed ID: 9373909
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer?
    Zhao T; Liao B; Yao J; Liu J; Huang R; Shen P; Peng Z; Gui H; Chen X; Zhang P; Zhu Y; Li X; Wei Q; Zhou Q; Zeng H; Chen N
    Prostate; 2015 Feb; 75(3):225-32. PubMed ID: 25307858
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Clinical studies of stage D2 prostatic cancer].
    Amano T; Oshinoya Y; Miyazaki K; Fujita Y; Hisazumi H
    Hinyokika Kiyo; 1993 Mar; 39(3):225-9. PubMed ID: 8506794
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Histopathological grading and DNA ploidy as prognostic markers in metastatic prostatic cancer.
    Jørgensen T; Yogesan K; Skjørten F; Berner A; Tveter KJ; Danielsen HE
    Br J Cancer; 1995 May; 71(5):1055-60. PubMed ID: 7734299
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Erythrocyte polyamines and prognosis in stage D2 prostatic carcinoma patients.
    Cipolla B; Guille F; Moulinoux JP; Bansard JY; Roth S; Staerman F; Corbel L; Quemener V; Lobel B
    J Urol; 1994 Mar; 151(3):629-33. PubMed ID: 7508520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.